{"id":"W4229911199","doi":"10.1016/j.urolonc.2011.11.013","title":"Commentary on “International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial.” Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, and the International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. Medical Research Council Clinical Trials Unit, London, United Kingdom","year":2012,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Vinblastine; Cisplatin; Methotrexate; Medicine; Bladder cancer; Chemotherapy; Urothelial cancer; Oncology; Internal medicine; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01584141,0.001855047,0.003654597,0.001549209,0.003523303,0.003167079,0.007391719,0.05473599,0.007321822],"category_scores_gemma":[0.07099305,0.001580944,0.004007237,0.002410685,0.004019381,0.004700725,0.001823938,0.05996409,0.008189962],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006989467,"about_ca_system_score_gemma":0.009314192,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01287789,"about_ca_topic_score_gemma":0.01657415,"domain_scores_codex":[0.988974,0.004289252,0.001426945,0.001485005,0.003036967,0.0007878127],"domain_scores_gemma":[0.9488578,0.035461,0.0026331,0.001052481,0.009035078,0.002960461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001519415,0.000007884223,0.00004866113,0.0001345775,0.00002489488,0.00007073754,0.00003255403,0.0000292063,0.0000541719,0.0004159364,0.9970193,0.00201016],"study_design_scores_gemma":[0.0009049561,0.0001818032,0.001475265,0.001779896,0.000297016,0.0004511847,0.0002342493,0.0004019738,0.0006302865,0.005398653,0.9881052,0.0001394936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0001884678,0.002292288,0.0001151965,0.9298808,0.06617034,0.00004156661,0.0004418493,0.00004925563,0.0008202877],"genre_scores_gemma":[0.0009249014,0.0008995058,0.0001512351,0.9563387,0.03934556,0.0001015764,0.0000989823,0.00002702158,0.002112506],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05473599,"threshold_uncertainty_score":0.08377838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5719069345010497,"score_gpt":0.5827083789599501,"score_spread":0.01080144445890041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}